Plaque Psoriasis Treatment Market size is valued at USD 18.0 billion in 2021 and is poised to grow at a significant CAGR of 10.0% over 2022–2028. As the prevalence of psoriasis rises worldwide, manufacturers are transforming breakthrough research into novel therapies by investing more in research. The number of medications approved for plaque psoriasis is constantly expanding, giving physicians and patients more treatment options. For instance, the FDA approved Eli Lilly’s interleukin inhibitor, the second chemical after Novartis’ Cosentyx. Companies are conducting various clinical trials and head-on-head trials with existing medications to create biologic therapies that will provide improved therapy alternatives for psoriasis patients. To encourage the acceptance of their breakthrough treatments, companies are increasingly offering co-pay choices to patients. According to the World Psoriasis Day consortium, psoriasis affects 125 million individuals worldwide. Novel systemic therapies using a variety of biologics are now being introduced. For instance, In April 2019, Ortho Dermatologics stated that an FDA-approved lotion for the treatment of psoriasis patients had been approved. The use of ‘Duobrii’ to treat plaque psoriasis has been authorized. Adults with plaque psoriasis will benefit from the product. In tandem with Duobrii to treat other significant psoriasis disorders, several efforts are being made to develop new products. The primary focus of the companies is on EU-5 and US countries to market the drugs. However, psoriasis incidence is higher in European countries like Netherlands, Norway, Denmark, and Austria and in Asia Pacific countries like China, Japan, and India. The expansion of the marketing of psoriasis drugs in these countries might provide an opportunity for the manufacturers to generate additional revenues. Celgene’s Otezla was launched in Germany, Switzerland, Austria, Scotland, and certain Scandinavian countries; the growth is expected from the expansion of the launch of OTEZLA in Europe and Japan markets, where it is well-positioned to repeat the success that is realized in the U.S. market. In October 2021, Sun Pharmaceutical Industries Ltd. announced the availability of ILUMYA in Canada to treat moderate-to-severe plaque psoriasis to strengthen its presence in Canada.